Latest Breaking News On - Overall immunology solution - Page 1 : vimarsana.com

Gracell Biotechnologies Announces FDA Clearance Of IND Application For Phase 1 Clinical Trial Of Fastcar-T GC012F As Early-Line Treatment Of Multiple

Gracell Biotechnologies Announces FDA Clearance Of IND Application For Phase 1 Clinical Trial Of Fastcar-T GC012F As Early-Line Treatment Of Multiple
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesWilliam caoGracell biotechnologies incDrug administrationChina national medical products administrationFierce life sciences innovationInvestigational new drugChief executive officerAmerican societyHematology annual meetingNational medical products administrationBiotech innovationLife sciences innovation awardsOverall immunology solutionBiotech breakthrough awards

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases

Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and.

United statesCayman islandsSusan galbraithHarney westwood riegelsWilliam caoGracell fasExchange commissionFierce life sciences innovationGracell biotechnologies incFreshfields bruckhaus deringerMaples groupAmerican depositary shareExecutive vice presidentAllbright law officesHarney westwoodBiotech innovation

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases - Gracell Biotechnologies (NASDAQ:GRCL)

Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy

Cayman islandsUnited statesGracell fasHarney westwood riegelsMarvin tang jessica laubSusan galbraithWilliam caoGracell biotechnologies incExchange commissionMaples groupFierce life sciences innovationFreshfields bruckhaus deringerAmerican depositary shareExecutive vice presidentAllbright law officesHarney westwood

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across

Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy manufacturing platform

Cayman islandsUnited statesWilliam caoHarney westwood riegelsGracell fasMarvin tang jessica laubSusan galbraithExchange commissionFreshfields bruckhaus deringerGracell biotechnologies incFierce life sciences innovationMaples groupAmerican depositary shareExecutive vice presidentAllbright law officesHarney westwood

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in.

United statesWilliam caoGracell biotechnologies incFierce life sciences innovationChina national medical products administrationExchange commissionDrug evaluationNational medical products administrationInvestigational new drugChief executive officerAmerican societyHematology annual meetingBiotech innovationLife sciences innovation awardsOverall immunology solutionBiotech breakthrough awards